Reports Q3 revenue $167.2M, consensus $158.94M. “Q3 was a solid quarter with steady commercial execution in glioblastoma, geographic expansion, and material progress for our clinical and product development pipelines,” said Ashley Cordova, CEO, Novocure (NVCR). “With four indications expected in market by year-end 2026, we are well on our way to becoming a platform therapy company – and we remain sharply focused on reaching profitability and expanding patient impact.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure reports Q3 EPS (33c), consensus (42c)
- NVCR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NovoCure’s Phase 3 Glioblastoma Study: A Potential Game-Changer in Cancer Treatment
- NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment
- NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment